Monoamine oxidase B
Monoamine oxidase B 詳細
| 英語名 | Monoamine oxidase B | 市販薬剤の数 | 3 |
| 治験薬の数 | 13 | ターゲットの別称 | EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4 |
| 研究＆開発段階 | Approved | ||
| 英語名 | Monoamine oxidase B |
| ターゲットの別称 | EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4 |
| 市販薬剤の数 | 3 |
| 治験薬の数 | 13 |
| 研究＆開発段階 | Approved |
Monoamine oxidase B 製品リスト
- 属性
Protein (1)
- 製品ライブラリ
オンライン (1)
- 種
Human (1)
- タグ
His Tag (1)
- マーカー
Unconjugated (1)
| 製品番号 | 種 | 発現システム | 製品説明 | タンパク質の構造 | 純度 | 特性 |
|---|---|---|---|---|---|---|
 Human | InsectCells | Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme) |  |  |
総数量1
- 1
Monoamine oxidase Bバックグランド
Monoamine Oxidase Type B (MAOB) is an enzyme located in the outer mitochondrial membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the breakdown of dopamine in the brain. MAOB inhibitors, that reduces dopamine turnover, are in clinical use for the treatment of Parkinson's disease (PD).
Monoamine oxidase B分子の別称
MAOB, MAO-B,Monoamine Oxidase B,Monoamine oxidase type B
ライセンシング
| プロジェクト | 薬物タイプ | 治療分野 | 適応症 | ステージ | エリア |
|---|---|---|---|---|---|
| Reversible MAOB Inhibitor | Small molecule | Neurological disease | Parkinson's disease | Phase I | Global |
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate | P2B-001 | Phase 3 Clinical | Pharma Two B Ltd | Parkinson Disease | 詳細 |
| Vafidemstat | ORY-2001 | Phase 2 Clinical | Oryzon Genomics Sa | Alzheimer Disease; Borderline Personality Disorder; Kabuki syndrome; Schizophrenia | 詳細 |
| J-147 | J-147 | Phase 2 Clinical | Salk Institute | Alzheimer Disease; Ischemic Stroke | 詳細 |
| Tisolagiline | KDS2010; KDS-2010 | Phase 2 Clinical | NeuroBiogen | Alzheimer Disease; Cognitive Dysfunction; Dementia; Obesity; Overweight | 詳細 |
| Rasagiline transdermal patch (Teikoku Pharma) | Phase 1 Clinical | Teikoku Pharma | Parkinson Disease | 詳細 | |
| SKL-PD | YKP-10461; SKL-PD | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Parkinson Disease | 詳細 |
| 18F-FCOB04 | 18F-FCOB04; 18F-FCOB-04 | Phase 1 Clinical | Peking Union Medical College Hospital | Neurodegenerative Diseases | 詳細 |
| LNTH-2511 | Phase 1 Clinical | Lantheus Holdings Inc | Neuroinflammatory Diseases | 詳細 | |
| Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma) | Phase 1 Clinical | Zhejiang Jingxin Pharmaceutical Co Ltd | Parkinson Disease | 詳細 | |
| Rasagiline Mesylate Sublingual membrane(Shanghai Shangyao Zhongxi Pharma) | Phase 1 Clinical | Shanghai Shangyao Zhongxi Pharmaceutical Co Ltd | Parkinson Disease | 詳細 | |
| Rasagiline Mesylate Transdermal Patch(world leader) | Phase 1 Clinical | Guizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd | Parkinson Disease | 詳細 | |
| HEC-122505MsOH | HEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOH | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Parkinson Disease | 詳細 |
| 18F-SMBT-1 | 18F-SMBT-1; 18-F-SMBT-1 | Clinical | Tohoku University | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rasagiline Mesylate | Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 | Approved | Teva | Azilect, Agilect | EU | Parkinson Disease | Teva Bv | 2005-02-21 | Alzheimer Disease; Dementia; Multiple System Atrophy; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Supranuclear Palsy, Progressive; Synucleinopathies | 詳細 |
| Selegiline Hydrochloride | FPF-1100; E-250 (free base) | Approved | Sanofi | FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline | Mainland China | Parkinson Disease | Chinoin Pharmaceutical And Chemical Works Co Ltd | 1989-06-05 | Amphetamine-Related Disorders; Borderline Personality Disorder; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder, Major; HIV Infections; Marijuana Abuse; Parkinson Disease; Schizophrenia; Tobacco Use Cessation; Tobacco Use Disorder | 詳細 |
| Safinamide Mesylate | PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743 | Approved | Newron Pharmaceutical | Xadago, Equfina | EU | Parkinson Disease | Zambon Spa | 2015-02-23 | Dyskinesia, Drug-Induced; Hepatic Insufficiency; Multiple System Atrophy; Parkinson Disease; Renal Insufficiency | 詳細 |
- 詳細
- 製品リスト
- 市販薬剤に関する情報
- 治験薬に関する情報